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Abstract
Purpose The association of a single nucleotide poly-
morphism of interleukin (IL)-10RB codon 47 with the
chronic hepatitis B virus (HBV) infection has been repor-
ted in two ethnic populations with different results, but not
in a Korean population. IL-10RB is a subunit of receptor
complexes for interferon-lambda (IFN-k) and IL-22, which
have antiviral and hepatocyte-protective activity, respec-
tively. This study examined the association of IL-10RB
K47E with the outcomes of HBV infection in Korean
subjects and the cellular response to these cytokines.
Methods Genotypes of IL-10RB and the outcomes of
HBV infection were analyzed in 1,000 Korean patients.
The effect of IFN-k or IL-22 on HBV replication and
cell viability was assessed in hepatoma cells expressing
IL-10RB K47 or E47. The transcript level of IL-10RB was
examined in Epstein Barr virus-transformed B cells and
hepatoma cells.
Results IL-10RB K47E was associated with chronic HBV
infection but not with hepatoma in the Korean population.
IL-10RB K47E was associated with the transcript level of
IL-10RB in transformed B cells but not with the responses
in hepatoma cells to IFN-k or IL-22. HBV replication or
5-fluorouracil-induced cell death was suppressed by treat-
ment of IFN-k or IL-22 in an IL-10RB K47E-independent
manner.
Conclusions IL-10RB K47E is related to chronic HBV
infection in a Korean population, but not to cellular
responsiveness to IFN-k and IL-22.
Keywords Chronic hepatitis B  HBV replication  IFN-k 
IL-10R2  IL-22  Single nucleotide polymorphism
Introduction
The interleukin (IL)-10RB subunit is shared by receptors
for IL-10, IL-22, IL-24, IL-26, and interferon-lambda
(IFN-k) [1]. Although IL-10RB is expressed in almost all
cells, these cytokines preferentially exert their functions in
specific tissues because of the restricted expression of
their specific receptor subunits [1]. IL-22R1 and IFN-kR
(IL-28R1) are expressed in hepatocytes, whereas IL-10R1
and IL-28R1 are expressed in leukocytes [1, 2]. IL-22
enhances the hepatocyte survival in a T cell-mediated
murine hepatitis model [3]. The antiviral effect of IFN-k
has been previously demonstrated with various viruses,
including hepatitis B virus (HBV) and human hepatitis C
virus [4, 5]. IFN-k also affects cell viability and plays
immunomodulatory roles in leukocytes [2, 6, 7].
HBV, a causative agent of chronic hepatitis leading to
liver cirrhosis and hepatocellular carcinoma (HCC), pref-
erentially replicates in hepatocytes [8]. HBV is a noncy-
topathic virus, and hepatocyte damage is not triggered by
virus replication itself but by the cellular immune response
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to viral antigens [8]. HBV clearance is mediated by the
immune response, and an insufficient immune response is
regarded as a determinant for the development of chronic
HBV infection [9]. Recently, the association of a cluster of
class II cytokine receptor genes on chromosome 21q22
with susceptibility to chronic HBV infection was reported
[10]. One gene in this locus is IL-10RB. Association of
IL-10RB K47E with the outcome of HBV infection has
been studied in two different populations with different
results [10–12].
The present study investigated the association of
IL-10RB K47E with the cellular responsiveness to IFN-k
and IL-22 and with the outcome of HBV infection in a
Korean population. The IL-10RB K47E polymorphism did
not affect the effects of IFN-k or IL-22 on the HBV rep-
lication and cell viability despite the association of
IL-10RB K47E with persistent HBV infection in a Korean
patient population.
Materials and methods
Vectors and recombinant viruses
IL-10RB DNA in pEF2-IL-10R2 (kindly provided by
Dr. Sergei Kotenko, New Jersey Medical School, Newark,
NJ, USA) was subcloned into pLXIN (Clontech, Mountain
View, CA, USA). An IL-10RB K47 allele expression
vector was produced using a site-directed mutagenesis
kit (Stratagene, La Jolla, CA, USA). IL-10RB DNA was
subcloned into pREP4, an episomal expression vector
(Invitrogen, Carlsbad, CA, USA). The leader sequences of
IL-10RB were replaced by the leader sequences of Igj in
pSecTag2b (Invitrogen). Flag-tag sequences were inserted
into the C termini of leader sequences. The inserted
nucleotide sequences of all constructs were verified by
sequencing analysis. Recombinant retroviruses were pro-
duced by the transfection of PT67 packaging cells with
pLXIN-IL-10RB and purified by the centrifugation of the
culture supernatant at 5,700g at 4 C for 16 h.
Cells
Hepatoma cell lines (Huh7 cells, HepG2 cells, Hep3B
cells, SNU182, SNU354, SNU368, SNU387, and SNU449;
Korean Cell Line Bank, Seoul, Korea) were used. Stable
cell clones were produced by the infection of Huh7 cells
with retroviruses expressing IL-10RB and then selected
with G418 (1 mg/ml) and cloned. Semistable transfectants
were produced by the transfection of Huh7 cells with
pREP4-IL-10RB. All experiments using semistable trans-
fectants were performed within 3 weeks of transfection
after two rounds of hygromycin selection.
Flow cytometric analysis
IL-10RB expression was analyzed by flow cytometry
using an anti-IL-10RB antibody (R&D Systems, Minne-
apolis, MN, USA) and a phycoerythrin-conjugated anti-
mouse IgG (H ? L) antibody (eBioscience, San Diego,
CA, USA) with FACS Canto (BD Biosciences, Rockville,
MD, USA).
Study subjects
From 2002 to 2008, 751 patients with chronic HBV
infection and 249 spontaneously recovered subjects were
enrolled from the Gastroenterology Department of Ajou
University Hospital in Korea. The diagnostic criterion for
chronic HBV infection was seropositivity for hepatitis B
surface antigen (HBsAg) for more than 6 months. The
study subjects were allocated to four groups according to
their HBV infection status, clinical data, and serological
profiles: (a) spontaneously recovered group, (b) chronic
hepatitis group, (c) liver cirrhosis group, and (d) HCC
group. The subjects in the spontaneously recovered group
were defined as HBsAg negative, antibody to hepatitis B
core antigen (anti-HBc IgG) positive, antibody to HBsAg
positive, and having no evidence of liver disease. The
subjects in the chronic hepatitis group had elevated ALT
(C2 times the upper limit of normal) at least once during
the follow-up period and were HBeAg positive or HBV
DNA positive. HBV DNA was detected by Digene Hybrid
Capture II Assay (Digene Diagnostics, Beltsville, MD,
USA) or the branched DNA assay (VersantTM 3.0; Bayer
Healthcare LLC Diagnostic Division, NY, USA). The
subjects in the liver cirrhosis group were diagnosed as
having liver cirrhosis based on typical morphologic find-
ings on computed tomography or ultrasonography and
corresponding laboratory features or evidence of portal
hypertension. The criteria for the diagnosis of HCC was
based on imaging and an AFP level[400 ng/ml. In case of
AFP \400 ng/ml, the diagnosis of HCC could be done by
having two typical dynamic imaging studies for, or one
typical imaging in, patients with cirrhosis, and a nodule[1
or 2 cm according to the Asia-Pacific Association of the
Study of the Liver (APASL) guidelines. The subjects who
were positive for anti-HBsAg and negative for anti-hepa-
titis B core IgG, positive for anti-human immunodeficiency
virus, or who had other types of chronic liver disease were
excluded from the study.
The general characteristics and clinical parameters of all
the subjects are shown in Table 1. All the study subjects
were Korean and therefore of a single ethnic population.
Informed consent was obtained from each subject, and the
Institutional Review Board of Human Research of Ajou
University Hospital approved the study protocol.
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Genotyping
Genotyping was performed using a GoldenGate genotyping
assay kit (Illumina Inc., San Diego, CA, USA) in accordance
with a standard protocol and the Sentrix array matrix chip
(Illumina Inc.). The chip was imaged using a BeadArray
Reader (Illumina Inc.). Genotyping analysis was performed
using Illumina’s BEADSTUDIO software (Version 3.0.22).
HBV core DNA isolation
HBV core DNA was isolated as described previously [13].
Huh7 cells were cotransfected with 500 ng of pEGFP-N1
(Clontech) and 2.5 lg of pPB [13] using Lipofectamine
2000 (Invitrogen) and harvested 48 h after transfection.
Twenty percent of cells were subjected to FACS analysis to
determine the transfection efficiency. Viral core particles
were isolated from the rest of the cells, and the HBV DNA
was extracted from core particles.
Real-time PCR and semiquantitative reverse
transcription-PCR
We performed real-time PCR for HBV DNA as described
[14, 15]. For real-time reverse transcription (RT)-PCR of the
IL-10RB transcript, we used a SYBR Green mixture (Applied
Biosystems, Foster City, CA, USA) and IL-10RB-specific
primers (TaKaRa Bio, Otsu, Japan). Semiquantitative RT-PCR
for IL-10RB was performed using 50-GGCTGAATTTGCA
GATGAGCATTC-30 and 50-GAAGACCGAGGCCATGAG
G-30. The band intensity of the PCR product was measured with
a densitometer (Gel Logic 200 Imaging System; Kodak). The
data were normalized to GAPDH.
Cell survival assay
The viability of cells was measured with a 3-[4,5-dimeth-
ylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
assay (Sigma). Cells were treated with 200 lM of 5-fluo-
rouracil (5-FU), an inhibitor of DNA synthesis, at 37 C for
2 days and then subjected to the MTT assay. Cell viability
was calculated as the percentage of the sample optical
density (OD) relative to the OD of uninfected cells. The
increment of viability was calculated as the difference
between the viabilities in the presence and absence of the
indicated cytokine.
Immunoblotting
STAT3 in cells was detected by immunoblotting using
antibody specific to STAT3 (Cell Signaling, Danvers, MA,
USA).
Luciferase reporter assay
Six tandem repeats of the STAT3 responsive element
were cloned into pGF1-mCMV, a lentiviral reporter
vector (System Biosciences, TR010PA-1). Cells were
infected with reporter lentivirus and 2 days later were
treated with the indicated cytokines. Luciferase activity
was measured using luciferin (Promega, Madison, WI,
USA) and a luminometer (Molecular Devices, Sunnyvale,
CA, USA).
Statistical analysis
For univariate analysis, the v2 test was used to analyze the
Hardy–Weinberg equilibrium of alleles at individual loci
and the independent sample t test was used to analyze
normally distributed continuous variables. Odds ratios with
95 % confidence intervals were computed by logistic
regression using SPSS version 11.0 software (SPSS, Chi-
cago, IL, USA). The odds ratios were adjusted for age and
sex as covariables. For all the statistical tests, significance
was set at P \ 0.05.
Results
Association of IL-10RB K47E with chronic HBV
infection, but not with HCC, in Korean subjects
The association of IL-10RB K47E (rs2834167) with
chronic HBV infection was studied in 194 sibling pairs
from the Gambia (the relative frequency for K47 allele was
93.9 %) [10] and 682 Chinese Han subjects (the relative
Table 1 General characteristics
of the study subjects
SR spontaneously recovered
subjects, CH chronic hepatitis
B, LC liver cirrhosis, HCC
hepatocellular carcinoma
Characteristics SR (n = 249) CH (n = 295) LC (n = 201) HCC (n = 255)
Gender (% M/F) 77.2/22.8 72.7/27.3 75.9/24.1 76.4/23.6
Age 44.1 ± 5.4 38.0 ± 9.1 46.2 ± 10.4 53.6 ± 10.3
AST (U/l) 31.9 ± 53.7 83.4 ± 121.3 75.0 ± 79.5 86.7 ± 100.2
ALT (U/l) 38.9 ± 28.9 113.1 ± 152.8 72.3 ± 99.1 50.8 ± 46.9
Total bilirubin (mg/dl) 0.9 ± 1.0 1.0 ± 1.6 2.1 ± 3.3 2.5 ± 11.2
Albumin (g/dl) 4.4 ± 0.2 4.2 ± 0.3 3.7 ± 0.7 3.6 ± 0.6
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frequency for K47 allele was 58.7 %) [12]. Similar
examinations have not hitherto been done in Korean
populations. Presently, the association of IL-10RB K47E
with outcomes of HBV infection was assessed in 1,000
Koreans, including 751 patients with chronic HBV
infection (including liver cirrhosis and HCC) and 249
patients who had spontaneously recovered from HBV
infection. The relative frequency of K47 allele in the
controls was 41 %, which was compatible with the fre-
quency in 934 Japanese volunteers in a previous study
[16]. IL-10RB K47 was associated with an increased risk
of a chronic HBV infection in the codominant model
(Table 2). However, there was no significant association
of IL-10RB K47E with HCC development (Table 3).
These findings support the suggestion that the risk fac-
tors for the development of HCC are different from
those for chronic HBV infection.
Association of IL-10RB K47E with its transcript levels
in B cells, but not in hepatoma cells
Surface and mRNA levels of IL-10RB are higher for the
E47 variant than the K47 variant [10]. Consistent with this,
significantly lower transcription of IL-10RB K47 than E47
was observed in Epstein–Barr virus (EBV)-transformed B
cells derived from homozygous Korean individuals
(Fig. 1a; P \ 0.001). However, similar levels of IL-10RB
expression were observed in hepatoma cell lines regardless
of their genotype (Fig. 1b).
IL-10RB K47E does not affect HBV replication
in response to IFN-k and IL-22
HBV replication in hepatoma cells expressing IL-10RB
K47 or E47 in response to IFN- k or IL-22 was deter-
mined to explore whether the single nucleotide poly-
morphism of an IL-10RB extracellular domain affects the
cellular response to IL-22 and IFN-k. First, Huh7 cells
were transfected with episomally maintained expression
vectors for each IL-10RB allele, and then IL-10RB mRNA
and surface protein levels were analyzed (Supplementary
Fig. a). Also, IL-10RB expression in Huh7 cells stably
transfected with retroviral expression vectors for IL-10RB
was verified by real-time RT-PCR (Supplementary Fig. b).
IL-10RB transcript and protein levels were higher in cells
with IL-10RB expression vectors than in control cells, but
were not affected by genotype. These cells were then
transfected with HBV plasmid and 24 h later were treated
with IFN-k or IL-22 for another 24 h. HBV replication was
analyzed by real-time PCR. HBV replication was inhibited
both by IFN-k and IL-22 in all these cells (Fig. 2a).
However, IL-10RB K47E did not affect the antiviral
effect of these cytokines. Next, HBV replication was
compared in four hepatoma cell lines. HBV replication
was slightly reduced in these cells in response to IFN- k
and IL-22, but the decrease was not associated with
IL-10RB K47E (Fig. 2b). These results supported the
suggestion that IL-10RB K47E does not directly affect
IFN-k- or IL-22-mediated suppression of HBV replication
in hepatocytes.
IL-10RB K47E does not influence the effect of IFN-k
and IL-22 on cell viability
Although HBV is not a cytotoxic virus, hepatocyte death
occurs as a result of the cell-mediated immune response to
the HBV antigen. Given that IL-22 promotes hepatocyte
survival in a T cell-mediated murine hepatitis model [3]
and IFN-k also affects cell viability [17], it was appropriate
to examine the influence of IL-10RB K47E on cell survival
in response to IFN-k and IL-22 when cell death was
induced by treatment with 5-FU, a chemotherapeutic agent
(Fig. 3). When cells were treated for 48 h with 5-FU,
viability was increased in the presence of IFN- k or IL-22,
but this change was not correlated with genotype. Notably,
populations of cells overexpressing IL-10RB were signifi-
cantly more viable than controls. These results imply that
the IL-10RB K47E does not affect hepatocyte response to
IFN-k and IL-22.
STAT3 activation is involved in the effect of IFN-k
and IL-22 on cell viability
The cell-protective effect of IFN-k was unpredicted.
Thus, to support the above results, the involvement of
STAT3 activation in IFN-k-mediated cell survival was
assessed, since it was revealed that STAT3 plays a
critical role in IL-22-mediated cell survival and that IFN-k
Table 2 Analysis of the association of an IL-10RB polymorphism (rs2834167) with chronic HBV infection versus self-limited HBV infection
Allele Codominant Dominant Recessive
OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value
A[G 1.25 (1.01, 1.54) 0.037 1.14 (0.68, 1.33) 0.087 1.18 (0.97, 1.42) 0.092
Genotype distributions and P values are shown for logistic analysis of three alternative models controlling for age and sex as covariates
OR odds ratio, CI confidence interval
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activates STAT3. First, STAT3 activation was analyzed
using a luciferase reporter assay (Fig. 4a). Luciferase
activity was increased by IFN-k treatment of cells. Next,
STAT3 expression was knocked down in Huh7 cells
using siRNA specific to STAT3 (Fig. 4b), and then the
cell viability of these cells was examined after treatment
with IFN-k or IL-22 (Fig. 4c). The increment of cell
viability was higher in control cells (untransfected or
control siRNA-transfected cells) by 10 ng/ml of cytokine
treatment than that in STAT3KD cells. These results
imply that IFN-k upregulates cell viability through STAT3
activation.
Table 3 Analysis of the association of an IL-10RB polymorphism (rs2834167) with HCC versus chronic HBV infection without HCC
Allele Codominant Dominant Recessive
OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value
A[G 1.084 (0.849, 1.385) 0.517 0.934 (0.771, 1.131) 0.486 1.231 (0.991, 1.528) 0.060
Genotype distributions and P values for logistic analysis of three alternative models controlling for age and sex as covariates are shown
OR odds ratio, CI confidence interval
Fig. 1 The IL-10RB expression levels in B cells and hepatoma cells.
The IL-10RB transcript was determined by real-time RT-PCR (a) or
semiquantitative RT-PCR (b) and surface protein levels were
determined by flow cytometry (b). a EBV-transformed human
peripheral B cell lines. The number of tested cell lines was 7 for
K47 and 12 for E47. b Hepatoma cell lines with known IL-10RB
genotype. Data are shown as the mean ± standard deviation of three
to five independent experiments. *Student’s t test
Fig. 2 IL-10RB K47E is not associated with the effect of IFN-k and
IL-22 on HBV replication. Cells were transfected with pPB, an HBV
plasmid, together with pEGFPN1 (1/5 of the amount of pPB) for
normalization of transfection efficiency. 1 day later, the cells were
treated with 100 ng/ml of IFN-k or IL-22 for 24 h. HBV core DNAs
were isolated from these cells and subjected to real-time PCR for
quantification of HBV DNA copy numbers. a Cells containing
episomally maintained vectors expressing IL-10RB E47 (E-fectant) or
K47 (K-fectant) and Huh7-derived stable clones expressing either
IL-10RB E47 (E47-8) or K47 (K47-19). CON without cytokine
treatment. b Hepatoma cell lines. Data represent the mean ± standard
deviation of five replicates
Hepatol Int (2013) 7:111–118 115
123
Discussion
Presently, the association of IL-10RB K47E with HBV
persistence was demonstrated in Korean subjects. How-
ever, IL-10RB K47E did not affect the cellular response to
IFN-k and IL-22. IL-10RB K47E affects responses to IL-10
because of differences in the expression level between IL-
10RB K47 and E47 [10]. However, a reduced responsive-
ness to IL-10, an immunosuppressive cytokine, in IL-10RB
K47 could not account for its association with chronic
HBV infection. Hence, the effect of this SNP on cellular
responsiveness to IFN-k and IL-22 capable of suppressing
HBV replication and increasing hepatoma cell viability
was examined. Although no direct influence of this SNP on
the cellular response to these cytokines was observed, the
cellular responsiveness was dependent on IL-10RB
expression level and a lower expression of IL-10RB K47
than E47 was shown in B cells. We do not know the reason
for the lack of association of IL-10RB K47E with IL-10RB
expression level in hepatoma cell lines, but the limited
number of hepatoma cell lines we analyzed may be one
factor. Alternatively, this SNP may be indirectly associated
with IL-10RB expression level. Concordant with this
speculation, a recent report described the linkage disequi-
librium of IL-10RB K47 with a SNP (rs999788C) in the
IL-10RB promoter lacking a NF-jB binding site [16]. In
that case, IL-10RB K47E may indirectly affect the cellular
response to IFN-k and IL-22. This study focused on the
association of IL-10RB K47E with the effects of IFN-k and
IL-22 in cultured hepatoma cells. Thus, the results may be
different in the human body, where cytokines binding to
IL-10RB affect hepatocytes directly and indirectly through
modulation of immune cells.
Fig. 3 Upregulation of cell survival by IFN-k and IL-22 is not
associated with IL-10RB K47E. Cells were treated with 200 lM of
5-FU in the presence or absence of the indicated cytokine (10 ng/ml)
at 37 C for 2 days. The cell viability was analyzed by a MTT assay.
E-fectant, K-fectant Cells containing episomally maintained vectors
expressing IL-10RB E47 or K47. HuH7, HepG2, SNU387 Hepatoma
cell lines with IL-10RB E47. Hep3B, SNU449 Hepatoma cell lines
with IL-10RB K47. Data represent the mean ± standard deviation of
five replicates. *P \ 0.05, Student’s t test
Fig. 4 IFN-k enhances cell survival through STAT3 activation.
a STAT3 activation in Huh7 cells was monitored by a luciferase
reporter assay. Data are shown as the mean ± standard deviation of
two independent experiments performed in triplicate. b STAT3
knock-down was assessed by immunoblotting in Huh7 cells (CON)
and cells transfected with a shRNA-expressing vector for a nonspe-
cific target (Scr) or specific to STAT3 (STAT3KD). c The viability of
cells treated with 200 lM 5-FU in the presence or absence of the
indicated cytokine at 37 C for 2 days was analyzed by a MTT assay.
Data are shown as the mean ± standard deviation of five independent
experiments
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The present results demonstrate the suppressive activity
of IL-22 and IFN-k on HBV replication. In contrast to IFN-
k, antiviral activity of IL-22 has not been well documented.
However, compatible with the present findings, a recent
report demonstrated that IL-22 shows weak inhibitory
effect on HBV replication in murine hepatocytes [18]. In
that report, the transcriptional program activated by IL-22
resembled more the response induced by IL-6 rather than
the INF-k-mediated response [18]. It is notable that IL-6
suppresses HBV replication through the inhibition of
nucleocapsid formation and of two transcription factors,
hepatocyte nuclear factor 1a and 4a, which are essential for
HBV gene expression and replication [19, 20]. Thus, the
current results suggest antiviral activity of IL-22 on HBV
in human cells. It will be interesting to find out the sup-
pressive mechanisms of IL-22 on HBV replication.
We showed the protective activity of IL-22 and IFN-k
on chemotherapy-induced hepatoma cell death. The pro-
tective effect of IL-22 is consistent with a previous report
that IL-22 contributes to the chemotherapeutic resistance of
human lung cancer cells through the activation of STAT3
[21]. Also, the aberrant expression of IL-22R1 and auto-
crine IL-22 stimulation contribute to tumorigenicity in
anaplastic large cell lymphoma [22]. However, the present
finding of a cell-protective effect of IFN-k is unexpected,
in light of the report that IFN-k inhibits the proliferation of
T lymphoma cells expressing IL-28R [17]. Comparable
with our results, though, IFN-b shows contradictory effects
on cell proliferation and apoptosis depending on the dose
[23]. Also, type 1 IFNs can stimulate cell survival or
apoptosis in myeloma cells depending on experimental
conditions [24–26]. As regulators of IFN-a-induced cell
survival, several molecules, such as G1P3 and USP18, are
recognized [27, 28]. In line with our results only three lines
among nine human esophageal carcinoma cell lines were
found to be sensitive to the antitumor effects of IFN-k
despite uniformly increased IFN-k-induced antiviral gene
expression [29]. The current findings provide evidence that
not only IL-22 but also IFN-k can stimulate cell survival
through involvement of STAT3 activation.
Participation of IL-10RB in STAT3 activation has been
previously suggested by the observations that STAT3 is
activated in cells transfected with both IL-10RB and IL-
22R1 or with both IL-10RB and IL-28R1, but not with
either receptor alone [30, 31]. STAT3 tyrosine phosphor-
ylation occurs through an interaction of STAT3 with the
IL-22R C terminus [32]. IFN-k-induced STAT3 tyrosine
phosphorylation has not been well studied, except that it
seems to be independent of IL-28R1 tyrosine residues 343
and 517 [17]. How the IL-10RB affects STAT3 tyrosine
phosphorylation requires further study.
In conclusion, the study results suggest that IL-10RB
K47E is associated with persistent HBV infection in a
Korean population, but not with cellular responsiveness to
IFN-k as well as IL-22.
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